MRX 5 - MicuRx Pharmaceuticals
Alternative Names: MRX 6038; MRX-5 - MicuRx PharmaceuticalsLatest Information Update: 23 Jul 2024
At a glance
- Originator MicuRx Pharmaceuticals
- Class Antibacterials; Antituberculars; Nonsteroidal anti-inflammatories; Organic boron compounds
- Mechanism of Action Leucyl-tRNA synthetase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Nontuberculous mycobacterium infections
- Preclinical Gram-negative infections
Most Recent Events
- 18 Jul 2024 Pharmacodynamic data form preclinical study in Nontuberculous mycobacterium infections released by MicuRx
- 20 Nov 2023 Phase-I clinical trials in Nontuberculous mycobacterium infections (In volunteers) in Australia (PO) (ACTRN12623001121651)
- 20 Nov 2023 Australian Ethics Commission for Human Research (HREC)approves application for MRX 5 in Non-tuberculous mycobacterial infections before November 2023